Autoimmune Metaplastic Atrophic Gastritis: Salvage Therapy When First-Line H. pylori Eradication Fails
In patients with autoimmune gastritis (AIG) and a confirmed active Helicobacter pylori infection who have completed a first-line eradication course without achieving confirmed eradication, a salvage protocol is indicated — particularly when there is no true penicillin allergy.
Clinical Scenario
Autoimmune gastritis with active H. pylori infection, in a patient without a true penicillin allergy. Testing and treating H. pylori in all AIG patients is recommended given the potential to exacerbate nutritional deficiencies and the implications for cancer risk.
Previous Treatment — Goal Not Achieved
First-line empiric eradication therapy (14 days) was completed but eradication was not confirmed: a test of cure — urea breath test, fecal antigen test, or biopsy-based test — performed at least 4 weeks after therapy did not return a negative result. This persistent infection is the escalation trigger for the salvage approach.
Salvage Treatment Approach (partial overview)
A 14-day empiric salvage eradication regimen is indicated. The specific combination chosen depends on which therapy was used in the prior course — several regimen options exist for treatment-experienced patients, each suited to a different prior-exposure history.
Treatment Goal
Eradication of H. pylori infection, confirmed by a negative test of cure — urea breath test, fecal antigen test, or biopsy-based test — performed at least 4 weeks after completion of therapy.
References
DOI: 10.14309/ajg.0000000000002968
- Given the implications of potentially undiagnosed H. pylori infection for cancer risk and exacerbating nutritional deficiencies (e.g., iron deficiency), H. pylori testing and treatment in all patients diagnosed with AIG are recommended.
- Of the recommended and suggested options for treatment-naive patients, only optimized BQT is suitable for patients with a true penicillin allergy.
- In treatment-experienced patients with persistent H. pylori infection who have not previously received BQT, optimized BQT is suggested (conditional recommendation; very low quality of evidence).
- In treatment-experienced patients with persistent H. pylori infection who have received BQT, rifabutin triple therapy is suggested (conditional recommendation; low quality of evidence).
- In treatment-experienced patients with persistent H. pylori infection, there is insufficient evidence from North America to recommend high-dose PPI or PCAB dual therapy (no recommendation; evidence gap).
- All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 weeks after completion of therapy.
View source ↗